4-chloro-2-(1-oxo-1,3,4,6,7,8,9,10-octahydro-2H-cyclohepta[4,5]pyrrolo[1,2-a]pyrazin-2-yl)nicotinaldehyde, 98%, 1g

4-Bromo-2-chloro-5-iodopyridine, 98%, 1g

(3S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid hydrochloride, 95.0%, 25g

GC capillary column ROTI®Cap-1701 MS, 60 m, 0.25 mm, 0.25 µm, 1 Piece(s)

3-Amino-4-fluorophenylboronic acid, 95.0%, 250mg

3-Pyridinecarboxamide, N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-, 98%, 1mg

Methyl 4-(trifluoromethoxy)benzoate, 97.0%, 1g

Irbesartan>98.0%(HPLC)(T)1g

POTASSIUM (MIX)-2-BUTEN-2-YLTRIFLUOROBORATE, 95.0%, 10g

2,3-Dimethyl-2,3-butanediamine dihydrochloride, 98.0%, 250mg

trans,trans-4-(trans-4-Butylcyclohexyl)-phenyl 4'-propylbicyclohexyl-4-carboxylate, 97%, 100g

1-(Tert-butyl) 4-ethyl 4-(4-methoxybenzyl)piperidine-1,4-dicarboxylate, 98%, 1g

6-(2-iodophenyl)-6-oxohexanoic acid, 97.0%, 2g